Items where authors include "Rawstron, A"

Article

Hillmen, P, Pitchford, A, Bloor, A et al. (29 more authors) (2023) Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (5). pp. 535-552. ISSN 1470-2045

Munir, T, Emmerson, J orcid.org/0000-0002-8198-8043, Hockaday, A et al. (9 more authors) (2022) Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial. British Journal of Haematology, 199 (5). pp. 707-719. ISSN 0007-1048

de Tute, RM, Pawlyn, C, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (14 more authors) (2022) Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology, 40 (25). pp. 2889-2900. ISSN 0732-183X

Allsup, DJ, Craig, Z orcid.org/0000-0001-9930-6648, Cairns, D orcid.org/0000-0002-2338-0179 et al. (13 more authors) (2022) Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors ADMIRE and ARCTIC trials: A comprehensive assessment of prognostic factors. American Journal of Hematology, 97 (5). E168-E171. ISSN 0361-8609

Allsup, D, Howard, D, Emmerson, J orcid.org/0000-0002-8198-8043 et al. (10 more authors) (2021) COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study. British Journal of Haematology. ISSN 0007-1048

Lamb, MJE, Smith, A, Painter, D et al. (9 more authors) (2021) Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open, 11 (2). e041296. ISSN 2044-6055

Norris, K, Hillmen, P orcid.org/0000-0001-5617-4403, Rawstron, A orcid.org/0000-0003-0798-9790 et al. (4 more authors) (2019) Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia, 33 (8). pp. 1953-1963. ISSN 0887-6924

Appleby, N, Eyre, TA, Cabes, M et al. (7 more authors) (2019) The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer, 19 (1). 471. ISSN 1471-2407

Varghese, AM, Rawstron, A orcid.org/0000-0003-0798-9790, Newton, D orcid.org/0000-0002-0214-1486 et al. (5 more authors) (2018) Highly selective SYK inhibitor, GSK143, abrogates survival signals in chronic lymphocytic leukaemia. British Journal of Haematology, 182 (6). pp. 927-930. ISSN 0007-1048

Md Yusof, MY orcid.org/0000-0003-3131-9121, Shaw, D, El-Sherbiny, Y orcid.org/0000-0003-4791-3475 et al. (4 more authors) (2017) Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 76 (11). pp. 1829-1836. ISSN 0003-4967

Arumugakani, G, Stephenson, SJ, Newton, DJ orcid.org/0000-0002-0214-1486 et al. (5 more authors) (2017) Early emergence of CD19-negative human antibody secreting cells at the plasmablast to plasma cell transition. Journal of Immunology, 198 (12). pp. 4618-4628. ISSN 0022-1767

Worrillow, L, Baskaran, P, Care, MA et al. (9 more authors) (2016) An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukemia cases using multiple polymerases. Oncogene, 35 (40). pp. 5328-5336. ISSN 0950-9232

Conference or Workshop Item

Arnold, J, Vital, E, Dass, S et al. (5 more authors) (2021) A Personalised Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in Anca-Associated Vasculitis. In: EULAR 2021, 02-05 Jun 2021, Virtual.

Rawstron, A, Cohen, D, de Tute, R et al. (8 more authors) (2015) BONE MARROW IS MORE SENSITIVE THAN PERIPHERAL BLOOD FOR DETECTION OF MRD IN CLL AND PROVIDES A MORE RELIABLE PREDICTION OF OUTCOME ACROSS DIFFERENT TREATMENTS. In: European Haematology Association Congress, 11-14 Jun 2015, Vienna, Austria.

Proceedings Paper

Munir, T, Howard, D orcid.org/0000-0003-3333-9783, McParland, L et al. (10 more authors) (2018) Obinutuzumab as consolidation after chemo-immunotherapy is highly effective in achieving MRD clearance from bone marrow and peripheral blood-Initial results of UK NCRI Phase II/III GALACTIC trial. In: British Journal of Haematology. 58th Annual Scientific Meeting of the British Society for Haematology, 16-18 Apr 2018, Liverpool, UK. Wiley , p. 79.

Holmes, K, Lefevre, P, Sadreev, I et al. (4 more authors) (2017) Ibrutinib mediates changes in chromatin structure in chronic lymphocytic leukaemia (CLL): epigenetic studies from the bloodwise TAP IcICLLe trial. In: Leukemia and Lymphoma. XVII International Workshop on Chronic Lymphocytic Leukemia, 12-15 May 2017, New York, USA. Taylor and Francis , pp. 19-20.

Md Yusof, MY orcid.org/0000-0003-3131-9121, Candelier, JB, Dass, S et al. (3 more authors) (2016) Validation of B Cell Depletion as A Predictor of Clinical Response and Efficacy of Retreatment of Non-Response in Rheumatoid Arthritis. In: Annals of the Rheumatic Diseases. Annual European Congress of Rheumatology (EULAR 2016), 08-11 Jun 2016, London, UK. BMJ Publishing Group , p. 731.

Md Yusof, MY orcid.org/0000-0003-3131-9121, Shaw, D, Rawstron, A et al. (2 more authors) (2016) Validation of Highly Sensitive Flow Cytometry as A Biomarker for Rituximab in Sle: A Rationale for More Intensive Treatment To Improve Clinical Outcomes. In: Annals of the Rheumatic Diseases. Annual European Congress of Rheumatology (EULAR 2016), 08-11 Jun 2016, London, UK. BMJ Publishing Group , p. 296.